Keeping Weight Off After GLP-1: A Procedure Posts Positive Pivotal Results

The GLP-1 medicines have changed how America loses weight. The harder question is what happens when the treatment stops, and one company is now testing a procedure built for exactly that moment.

The success of the GLP-1 medicines has created a problem the field did not have before. Millions of people can now lose a significant amount of weight. Far fewer have a proven way to keep it off once the medicine ends, and weight regain after treatment stops has become the open question in obesity care.

Fractyl Health reported this week that Revita, its procedure designed for weight maintenance after GLP-1 treatment, met the main goal of its pivotal study. In the REMAIN 1 pivotal cohort, patients who received the procedure regained significantly less weight over six months than patients who received a sham procedure, a result the company reported with a p value of 0.0023.

Revita is not another medicine. It is a procedure, performed once, and it is intended for the period after a patient has lost weight on a GLP-1 medicine and stopped taking it. The company is now focusing its resources on this single program and plans to file for FDA authorization through the De Novo pathway later this year. That is the route the FDA uses for first of its kind devices. Twelve month results from the study are expected in early 2027.

The caution belongs in the same paragraph as the promise. Revita is investigational. It is not authorized by the FDA, it is not available to patients, and six month results in one study cohort do not settle how durable the effect is, how it performs across different patient groups, or whether regulators will judge the benefit sufficient. The twelve month data will matter more than the six month data, and the FDA will have the final word.

Even with those limits, the direction of travel is worth noting. Obesity care is moving from a single question, how much weight can a patient lose, to a harder one, how long can a patient keep it off. Maintenance is likely to be one of the central conversations at ObesityWeek in November, and it is the question every serious program in this field now has to answer.

For patients and the clinicians who care for them, that is the right question to be asking. Losing weight changes a life. Keeping it off is what changes a lifetime.

Source: Fractyl Health announcement, October 22, 2026, via GlobeNewswire. Revita is an investigational procedure and has not been authorized by the US Food and Drug Administration.